Last reviewed · How we verify
MW031
MW031 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity.
MW031 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity. Used for Oncology indication (specific indication not publicly disclosed).
At a glance
| Generic name | MW031 |
|---|---|
| Also known as | Recombinant anti-RANKL human monoclonal antibody injection |
| Sponsor | Mabwell (Shanghai) Bioscience Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While the exact molecular target of MW031 is not publicly detailed, it is being developed by Mabwell as an oncology therapeutic in Phase 3 trials. Based on the company's pipeline focus, it likely functions as an immune checkpoint inhibitor or tumor-targeting antibody designed to engage the immune system against cancer cells.
Approved indications
- Oncology indication (specific indication not publicly disclosed)
Common side effects
Key clinical trials
- A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis (PHASE3)
- Efficacy and Safety of MW031 in PMO Subjects (PHASE3)
- Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |